{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:44:20Z","timestamp":1788057860421,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006098","name":"Radiological Society of North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005625","name":"RSNA Research and Educational Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clgc.2024.102229","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T09:26:51Z","timestamp":1729243611000},"page":"102229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patterns of Failure After Definitive Trimodality Therapy for Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9737-5033","authenticated-orcid":false,"given":"Nikhil V.","family":"Kotha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2306-8863","authenticated-orcid":false,"given":"Abhishek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Riviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler J.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund M.","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Salmasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-0350","authenticated-orcid":false,"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent S.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8170-264X","authenticated-orcid":false,"given":"Tyler F.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clgc.2024.102229_bib0001","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41585-019-0199-x","article-title":"Organ preservation in bladder cancer: an opportunity for truly personalized treatment","volume":"16","author":"Song","year":"2019","journal-title":"Nat Rev Urol"},{"issue":"19","key":"10.1016\/j.clgc.2024.102229_bib0002","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1001\/jama.2020.17601","article-title":"Bladder cancer","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA - J Am Med Assoc"},{"issue":"1","key":"10.1016\/j.clgc.2024.102229_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2012.08.009","article-title":"ICUD-EAU international consultation on bladder cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder","volume":"63","author":"Gakis","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102229_bib0004","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2008.07.018","article-title":"potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience","volume":"55","author":"Donat","year":"2009","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102229_bib0005","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2012.11.015","article-title":"Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the national cancer data Base","volume":"63","author":"Gray","year":"2013","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102229_bib0006","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2017.03.038","article-title":"Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder","volume":"72","author":"Seisen","year":"2017","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.clgc.2024.102229_bib0007","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamasurg.2018.1680","article-title":"Comparing survival outcomes and costs associated with radical cystectomy and trimodal therapy for older adults with muscle-invasive bladder cancer","volume":"153","author":"Williams","year":"2018","journal-title":"JAMA Surg"},{"issue":"4","key":"10.1016\/j.clgc.2024.102229_bib0008","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2017.04.028","article-title":"Trimodal therapy is inferior to radical cystectomy for muscle-invasive bladder cancer using population-level data: is there evidence in the (lack of) details?","volume":"72","author":"Kulkarni","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102229_bib0009","unstructured":"Corporate data warehouse (CDW). Available at: https:\/\/www.hsrd.research.va.gov\/for_researchers\/vinci\/cdw.cfm. Accessed December 19, 2020."},{"key":"10.1016\/j.clgc.2024.102229_bib0010","series-title":"Facility Oncology Registry Data Standards Revised for 2016","year":"2016"},{"issue":"6","key":"10.1016\/j.clgc.2024.102229_bib0011","doi-asserted-by":"crossref","first-page":"693","DOI":"10.7205\/MILMED-D-11-00434","article-title":"Cancer incidence among patients of the U.S. veterans affairs health care system","volume":"177","author":"Zullig","year":"2012","journal-title":"Mil Med"},{"issue":"1","key":"10.1016\/j.clgc.2024.102229_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"4","key":"10.1016\/j.clgc.2024.102229_bib0013","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2215\/CJN.11721018","article-title":"Estimation of kidney function in oncology","volume":"14","author":"Casal","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102229_bib0014","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2024.102229_bib0015","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ijrobp.2015.10.051","article-title":"Patterns of failure after radical cystectomy for pt3-4 bladder cancer: implications for adjuvant radiation therapy this work will be presented at the 12th annual american society of clinical oncology genitourinary cancers symposium, january 7-9, 2016","volume":"94","author":"Reddy","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"34","key":"10.1016\/j.clgc.2024.102229_bib0016","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: A pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clgc.2024.102229_bib0017","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clgc.2024.102229_bib0018","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the massachusetts general hospital experience","volume":"71","author":"NJ","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102229_bib0019","first-page":"1","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials 2015 161"},{"issue":"8","key":"10.1016\/j.clgc.2024.102229_bib0020","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2024.102229_bib0021","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2147\/CMAR.S287904","article-title":"Treatment options for metastatic urothelial carcinoma after first-line chemotherapy","volume":"14","author":"Tassinari","year":"2022","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clgc.2024.102229_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211047352","article-title":"Metastatic Urothelial Cancer: a rapidly changing treatment landscape","volume":"13","author":"Stecca","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102229_bib0023","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MOU.0000000000000201","article-title":"Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma","volume":"25","author":"DiBianco","year":"2015","journal-title":"Curr Opin Urol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102229_bib0024","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/1533034617691409","article-title":"Incidental dose to pelvic nodes in bladder-only radiotherapy: is it clinically relevant?","volume":"16","author":"Lewis","year":"2017","journal-title":"Technol Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clgc.2024.102229_bib0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clon.2019.07.017","article-title":"The intensity-modulated pelvic node and bladder radiotherapy (IMPART) trial: a phase ii single-centre prospective study","volume":"32","author":"Tan","year":"2020","journal-title":"Clin Oncol (Royal Coll Radiol (Great Britain)"},{"issue":"1","key":"10.1016\/j.clgc.2024.102229_bib0026","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102229_bib0027","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102229_bib0028","article-title":"Treatment discontinuation in patients with muscle-invasive bladder cancer undergoing chemoradiation","volume":"7","author":"Kotha","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102229_bib0029","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.clgc.2024.102229_bib0030","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00345-018-2371-y","article-title":"Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era","volume":"36","author":"Fletcher","year":"2018","journal-title":"World J Urol"},{"issue":"8","key":"10.1016\/j.clgc.2024.102229_bib0031","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1158\/1055-9965.EPI-18-1280","article-title":"Social determinants of appropriate treatment for muscle-invasive bladder cancer","volume":"28","author":"Washington","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Suppl 5","key":"10.1016\/j.clgc.2024.102229_bib0032","doi-asserted-by":"crossref","first-page":"S542","DOI":"10.21037\/tau.2019.12.22","article-title":"Commentary: underutilization of curative-intent therapy for patients with muscle-invasive bladder cancer in Sweden mimics the United States","volume":"8","author":"Clinton","year":"2019","journal-title":"Transl Androl Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400199X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400199X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T15:20:40Z","timestamp":1753111240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732400199X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S155876732400199X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102229","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of Failure After Definitive Trimodality Therapy for Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102229"}}